Dr Luca Malorni discusses how resistance to CDK4/6 inhibitors develops in patients with HR+/HER2- advanced breast cancer and how molecular biomarkers may be used in the future to optimize treatment choices.1/3 Next Interview
Prof. Aleix Prat presents the most recent data on the prognostic value of molecular intrinsic subtyping in HR+/HER2- breast cancer and its value in predicting response to CDK4/6 inhibitors.2/3 Next Interview
Dr Barbara Pistilli presents the most recent clinical evidence on the effect of different patient characteristics, including menopausal status, age, sensitivity to endocrine therapy and metastases, on CDK4/6 inhibitor therapy in HR+/HER2- breast cancer.
3/3 Leave Feedback
Overview & Learning Objectives
In this activity, leading experts in breast cancer provide updates on biomarkers for response to CDK4/6 inhibitors, the prognostic value of intrinsic subtypes and clinical characteristics which can help guide treatment decisions.
After watching this activity, participants should be better able to:
- Recall the most recent data on potential biomarkers of response to CDK4/6 inhibitors
- Evaluate the impact of intrinsic subtypes on treatment selection and outcomes in advanced breast cancer
- Discuss how different patient characteristics may impact choice of CDK4/6 inhibitor for patients with HR+/HER2- advanced breast cancer